Methods for the prevention and the treatment of extracapillary glomerulonephritis

Patent metadata

Field	Value
Publication number	US-2017342415-A1
Application number	US-201715672384-A
Country	US
Kind code	A1
Filing date	Aug 9, 2017
Priority date	Jan 23, 2014
Publication date	Nov 30, 2017
Grant date	—

Abstract

The present invention relates to the prevention and the treatment of extracapillary glomerulonephritis such as rapidly progressive glomerulonephritis and collapsing glomerulonephritis.

First claim

1 - 5 . (canceled)

6 . A method of identifying a subject having or at risk of having or developing extracapillary glomerulonephritis, comprising a step of measuring in a sample obtained from said subject the expression level of miR-92a.

7 . The method according to claim 6 wherein said extracapillary glomerulonephritis is a rapidly progressive glomerulonephritis or a collapsing glomerulopathy.

8 . The method according to claim 6 which further comprises a step of comparing the expression level of miR-92a in the sample with a control, wherein detecting a differential in the expression level of the miR-92a between the sample and the control is indicative of the subject having or at risk of having or developing an extracapillary glomerulonephritis, a rapidly progressive glomerulonephritis or a collapsing glomerulopathy.

9 . A method of preventing or treating extracapillary glomerulonephritis in a subject in need thereof comprising the steps of:
i) providing a sample from a subject, ii) measuring the expression level of miR-92a in the sample obtained at step i), iii) comparing said expression level measured in step ii) with a control, wherein high expression level of miR-92a is indicative of subject having or at risk of having or developing an extracapillary glomerulonephritis, and iv) treating said subject having or at risk of having or developing an extracapillary glomerulonephritis with a miR-92a inhibitor compound and/or an extracapillary glomerulonephritis treatment.

10 . The method according to claim 9 wherein said extracapillary glomerulonephritis is a rapidly progressive glomerulonephritis and said extracapillary glomerulonephritis treatment is a rapidly progressive glomerulonephritis treatment.

11 . The method according to claim 10 wherein said rapidly progressive glomerulonephritis (RPGN) treatment is cyclophosphamide, plasmapheresis, anti-CD20 antibody, mycophenolate mofetil and corticosteroids such as methylprednisolone or prednisone.

12 . The method according to claim 9 wherein said extracapillary glomerulonephritis is a collapsing glomerulopathy and said extracapillary glomerulonephritis treatment is a collapsing glomerulopathy treatment.

13 . The method according to claim 12 wherein said collapsing glomerulopathy (CG) treatment is steroids or cyclosporine, angiotensin converting enzyme inhibitors and/or angiotensin II receptor blockers, anti-HIV therapy, lipid lowering agents and mycophenolate mofetil.

14 . A method for monitoring the treatment of a subject affected with an extracapillary glomerulonephritis comprising the steps consisting of:
i) diagnosis of extracapillary glomerulonephritis before said treatment, ii) diagnosis of extracapillary glomerulonephritis after said treatment, iii) and comparing the results determined a step i) with the results determined at step ii) wherein a difference between said results is indicative of the effectiveness of the treatment, and wherein steps i) and ii) are each performed by the method of claim 6 .

15 . The method according to claim 14 wherein said extracapillary glomerulonephritis is a rapidly progressive glomerulonephritis and said extracapillary glomerulonephritis treatment is a rapidly progressive glomerulonephritis treatment.

16 . The method according to claim 15 wherein said rapidly progressive glomerulonephritis (RPGN) treatment is cyclophosphamide, plasmapheresis, anti-CD20 antibody, mycophenolate mofetil and corticosteroids such as methylprednisolone or prednisone.

17 . The method according to claim 14 wherein said extracapillary glomerulonephritis is a collapsing glomerulopathy and said extracapillary glomerulonephritis treatment is a collapsing glomerulopathy treatment.

18 . The method according to claim 17 wherein said collapsing glomerulopathy (CG) treatment is steroids or cyclosporine, angiotensin converting enzyme inhibitors and/or angiotensin II receptor blockers, anti-HIV therapy, lipid lowering agents and mycophenolate mofetil.

Assignees

• Inserm (Institut National De La Sante Et De La Rech Medicale)
• Univ Paris Descartes

Inventors

• Tharaux Pierre-Louis
• Henique-Greciet Carole

Classifications

• A61P13/12

  of the kidneys · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12N2310/113

  targeting other non-coding nucleic acids, e.g. antagomirs · CPC title

• C12Q1/6883

  for diseases caused by alterations of genetic material · CPC title

• A61K31/7088

  Compounds having three or more nucleosides or nucleotides · CPC title